| Bioactivity | CG347B is a selective HDAC6 inhibitor, also involves in synthesis of other metalloenzyme inhibitors. HDAC6 inhibitors can be used for oncology, immunology, and neurology research[1][2]. | ||||||||||||
| Invitro | HtrA1 is identified as a Cisplatin (HY-17394, CDDP) resistance-related gene in NSCLC cells, while CG347B shows no effect on normalized mRNA expression or protein level of HtrA1 in NCI-H460 (CDDP-resistant) cells[1].CG347B (200 nM; 48 h) slightly rescues the Foxp3 expression inhibition induced by IL-4 (15 ng/mL), indicating a potential inhibition happens on histone deacetylation in naive CD4+ T cells from WT B6 mice cultured under Treg-polarizing conditions (for 1-3 d)[3]. | ||||||||||||
| Name | CG347B | ||||||||||||
| CAS | 1598426-03-9 | ||||||||||||
| Formula | C16H17N3O2 | ||||||||||||
| Molar Mass | 283.33 | ||||||||||||
| Appearance | Solid | ||||||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | ||||||||||||
| Storage |
|
||||||||||||
| Reference | [1]. Wang W, et al. Characterization of a novel HDAC/RXR/HtrA1 signaling axis as a novel target to overcome cisplatin resistance in human non-small cell lung cancer. Mol Cancer. 2020 Sep 2;19(1):134. [2]. Christopher M. YATES. Metalloenzyme inhibitor compounds. WO2018165520A1. [3]. Cui J, et al. IL-4 inhibits regulatory T cells differentiation by HDAC9-mediated epigenetic regulation. Cell Death Dis. 2021 May 18;12(6):501. |